SAINT-CLOUD, France (ots/PRNewswire) – Ethypharm has entered into an agreement with Mitsubishi Tanabe Pharma Corporation (MTPC) to acquire the selective antithrombin active ingredient Argatroban monohydrate (Argatra®, Arganova®, Novastan®, Exembol®) in Europe.
Ethypharm, known for its expertise in the treatment of central nervous system diseases (including severe pain and addiction) and injectable medicines for hospitals, aims to strengthen its established pharmaceutical business in Europe through internal development, licensing and acquisitions.
In Europe, MTPC received the first approval for argatroban in Sweden in 2004, and the product is currently available in 13 countries, including Germany, the United Kingdom, France, Spain and Italy, for the treatment of heparin-induced thrombocytopenia (HIT) type II. Heparin-induced thrombocytopenia (HIT) type II is a serious condition that carries the risk of fatal thromboembolic complications. Argatroban is an anticoagulant with a short half-life in the bloodstream that is metabolized in the liver. Therefore, it is suitable for patients after surgery and for patients with kidney disease who may develop HIT type II.
Denis Delval, CEO of Ethypharm, said: “We are pleased to strengthen our portfolio of key medicines and make Argatroban available to patients in Europe. Furthermore, we are proud to acquire this product from its originator, the renowned Mitsubishi Tanabe Pharma Corporation.“
About Ethypharm
Ethypharm is a leading mid-sized international pharmaceutical company with strong European roots, manufacturing and supplying essential medicines with a focus on hospital care, central nervous system (severe pain and addiction) and internal medicine.
Ethypharm is committed to improving the lives of patients and making a positive impact on society and the environment.
Ethypharm employs 1,700 people for its various pharmaceutical activities, including 1,400 in the industrial sector.
The six manufacturing sites in France, the United Kingdom, Spain and China have expertise in injectable medicines and complex solid oral forms.
With a global presence in 68 countries, the company sells its products directly in Europe and China and maintains strategic partnerships in the EMEA, NA, LATAM and APAC markets.
Ethypharm works closely with authorities and healthcare professionals to ensure that its medicines are used properly and that patients have access to them.
For more information about Ethypharm, see http://www.ethypharm.com.
About Mitsubishi
In Europe, the MTPC subsidiary Mitsubishi Tanabe Pharma Europe Ltd (hereinafter referred to as “MTPE”), based in London, United Kingdom, and the MTPE subsidiary Mitsubishi Tanabe Pharma GmbH (hereinafter referred to as “MTPD”), based in Düsseldorf, Germany, actively involved in the marketing and sales of Argatroban in the UK and Germany, as well as other European countries, through their respective partner networks.
Mitsubishi Tanabe Pharma Corporation (Chuo-ku, Osaka; Deputy Director: Akihiro Tsujimura; hereinafter “MTPC”), a member of the Mitsubishi Chemical Group, remains committed to supplying pharmaceutical products to patients in Europe through MTPE and MTPD. This includes the continued supply of Radicava® (edaravone), a treatment for amyotrophic lateral sclerosis, through its European operations, making a meaningful contribution to disease-affected people in the region.
The company’s six manufacturing facilities are located in France, the United Kingdom, Spain and China.
About Mitsubishi Tanabe Pharma Group
Mitsubishi Tanabe Pharma Corporation (MTPC), a Mitsubishi Chemical Group company, is committed to supplying patients in Europe with pharmaceutical products through Mitsubishi Tanabe Pharma Europe Ltd (MTPE) and Mitsubishi Tanabe Pharma GmbH (MTPD). . This also includes the continued supply of Radicava® (Edaravone), the drug used to treat amyotrophic lateral sclerosis, which makes a meaningful contribution to those affected in the region. In Europe, MTPE and its subsidiary MTPD have been actively involved in the marketing and sales of Argatroban in the United Kingdom and Germany, as well as other European countries, through their respective partner networks.
Logo: https://mma.prnewswire.com/media/2434581/Ethypharm_Logo.jpg
Media contact:
April Ponnelle
Ethypharm
presse@ethypharm.com
View original content:https://www.prnewswire.com/news-releases/erwerb-des-argatroban-geschafts-in-europa-302179245.html
Questions & Contact:
+ 33 (0)6 30 51 25 27